The role of T-cells in the pathogenesis of myelodysplastic syndromes: Passengers and drivers

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 201-203

  Fozza, Claudio ^a   Longinotti, Maurizio ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; T LYMPHOCYTE RECEPTOR; TALMAPIMOD; THALIDOMIDE;

BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COCULTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LETTER; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

HUMANS; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84872412514     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.007     Document Type: Letter

References (28)

1. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
2. Maciejewski J.P., Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma 2004, 45:433-440.
3. Giannouli S., Voulgarelis M., Zintzaras E., Tzioufas A.G., Moutsopoulos H.M. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology 2004, 43:626-632.
4. Smith M.A., Smith J.G. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991, 15:597-601.
5. Fozza C., Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. Eur J Haematol 2012, 88:380-387.
6. Epperson D.E., Nakamura R., Saunthararajah Y., Melenhorst J., Barrett A.J. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001, 25:1075-1083.
7. Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
8. Epling-Burnette P.K., Painter J.S., Rollison D.E., et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007, 21:659-667.
9. Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
10. Pülhorn H., Herrmann M., Harms H., Jung A., Baumann I. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome. Histopathology 2012, 61:200-211.
11. Meers S., Vandenberghe P., Boogaerts M., Verhoef G., Delforge M. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients. Leuk Res 2008, 32:1026-1035.
12. Jacobs N.L., Holtan S.G., Porrata L.F., Markovic S.N., Tefferi A., Steensma D.P. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010, 85:160-163.
13. Kordasti S.Y., Ingram W., Hayden J., et al. CD4+CD25 high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
14. Fozza C., Nadal E., Longinotti M., Dazzi F. T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T-cells and their CD4+CD25- counterpart. Haematologica 2007, 92:206-214.
15. Kotsianidis I., Bouchliou I., Nakou E., et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
16. Alfinito F., Sica M., Luciano L., et al. Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 2010, 148:90-98.
17. Fozza C., Longu F., Contini S., et al. Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127 (low) regulatory T cells. Acta Haematol 2012, 128:178-182.
18. Mailloux A.W., Sugimori C., Komrokji R.S., et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012, 189:3198-3208.
19. Kordasti S.Y., Afzali B., Lim Z., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
20. Bouchliou I., Miltiades P., Nakou E., et al. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. Clin Immunol 2011, 139:350-359.
21. Fozza C., Contini S., Virdis P., et al. Patients with myelodysplastic syndromes show reduced frequencies of CD4(+) CD8(+) double-positive T cells. Eur J Haematol 2012, 88:89-90.
22. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314-1322.
23. Raza A., Candoni A., Khan U., et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004, 45:2099-2104.
24. Navas T.A., Mohindru M., Estes M., et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006, 10:4170-4177.
25. Jonásova A., Neuwirtová R., Cermák J., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100:304-309.
26. Keilholz U., Letsch A., Busse A., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
27. Sloand E.M., Melenhorst J.J., Tucker Z.C., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
28. Lee S.E., Kim Y.J., Yahng S.A., et al. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur J Haematol 2011, 87:510-520.